Lu Wu1,2, Diamantis I Tsilimigras1, Anghela Z Paredes1, Rittal Mehta1, J Madison Hyer1, Katiuscha Merath1, Kota Sahara1, Fabio Bagante1, Eliza W Beal1, Feng Shen2, Timothy M Pawlik3. 1. Department of Surgery, Division of Surgical Oncology, The Urban Meyer III and Shelley Meyer Chair for Cancer Research, Professor of Surgery, Oncology, Health Services Management and Policy, The Ohio State University Wexner Medical Center and James Cancer Hospital and Solove Research Institute, 395 W. 12th Ave., Suite 670, Columbus, OH, USA. 2. Department of Hepatobiliary Surgery, Eastern Hepatobiliary Surgery Hospital, Second Military Medical University, Shanghai, China. 3. Department of Surgery, Division of Surgical Oncology, The Urban Meyer III and Shelley Meyer Chair for Cancer Research, Professor of Surgery, Oncology, Health Services Management and Policy, The Ohio State University Wexner Medical Center and James Cancer Hospital and Solove Research Institute, 395 W. 12th Ave., Suite 670, Columbus, OH, USA. tim.pawlik@osumc.edu.
Abstract
INTRODUCTION: Intrahepatic cholangiocarcinoma (ICC) remains an uncommon disease with a rising incidence worldwide. We sought to identify trends in therapeutic approaches and differences in patient outcomes based on facility types. METHODS: Between January 1, 2004, and December 31, 2015, a total of 27,120 patients with histologic diagnosis of ICC were identified in the National Cancer Database and were enrolled in this study. RESULTS: The incidence of ICC patients increased from 1194 in 2004 to 3821 in 2015 with an average annual increase of 4.16% (p < 0.001). Median survival of the cohort improved over the last 6 years of the study period (2004-2009: 8.05 months vs. 2010-2015: 9.49 months; p < 0.001). Among surgical patients (n = 5943, 21.9%), the incidence of R0 resection, lymphadenectomy and harvest of ≥6 lymph nodes increased over time (p < 0.001). Positive surgical margins (referent R0: R1, HR 1.49, 95% CI 1.24-1.79, p < 0.001) and treatment at community cancer centers (referent academic centers; HR 1.24, 95% CI 1.04-1.49, p = 0.023) were associated with a worse prognosis. Patients treated at academic centers had higher rates of R0 resection (72.4% vs. 67.7%; p = 0.006) and lymphadenectomy (55.6% vs. 49.5%, p = 0.009) versus community cancer centers. Overall survival was also better at academic versus community cancer programs (median OS: 11 months versus 6 months, respectively; p < 0.001). CONCLUSIONS: The incidence of ICC has increased over the last 12 years in the USA with a moderate improvement in survival over time. Treatment at academic cancer centers was associated with higher R0 resection and lymphadenectomy rates, as well as improved OS for patients with ICC.
INTRODUCTION:Intrahepatic cholangiocarcinoma (ICC) remains an uncommon disease with a rising incidence worldwide. We sought to identify trends in therapeutic approaches and differences in patient outcomes based on facility types. METHODS: Between January 1, 2004, and December 31, 2015, a total of 27,120 patients with histologic diagnosis of ICC were identified in the National Cancer Database and were enrolled in this study. RESULTS: The incidence of ICC patients increased from 1194 in 2004 to 3821 in 2015 with an average annual increase of 4.16% (p < 0.001). Median survival of the cohort improved over the last 6 years of the study period (2004-2009: 8.05 months vs. 2010-2015: 9.49 months; p < 0.001). Among surgical patients (n = 5943, 21.9%), the incidence of R0 resection, lymphadenectomy and harvest of ≥6 lymph nodes increased over time (p < 0.001). Positive surgical margins (referent R0: R1, HR 1.49, 95% CI 1.24-1.79, p < 0.001) and treatment at community cancer centers (referent academic centers; HR 1.24, 95% CI 1.04-1.49, p = 0.023) were associated with a worse prognosis. Patients treated at academic centers had higher rates of R0 resection (72.4% vs. 67.7%; p = 0.006) and lymphadenectomy (55.6% vs. 49.5%, p = 0.009) versus community cancer centers. Overall survival was also better at academic versus community cancer programs (median OS: 11 months versus 6 months, respectively; p < 0.001). CONCLUSIONS: The incidence of ICC has increased over the last 12 years in the USA with a moderate improvement in survival over time. Treatment at academic cancer centers was associated with higher R0 resection and lymphadenectomy rates, as well as improved OS for patients with ICC.
Authors: Giorgio Ercolani; Gaetano Vetrone; Gian Luca Grazi; Osamu Aramaki; Matteo Cescon; Matteo Ravaioli; Carla Serra; Giovanni Brandi; Antonio Daniele Pinna Journal: Ann Surg Date: 2010-07 Impact factor: 12.969
Authors: Fabio Bagante; Gaya Spolverato; Matthew Weiss; Sorin Alexandrescu; Hugo P Marques; Luca Aldrighetti; Shishir K Maithel; Carlo Pulitano; Todd W Bauer; Feng Shen; George A Poultsides; Oliver Soubrane; Guillaume Martel; B Groot Koerkamp; Alfredo Guglielmi; Endo Itaru; Timothy M Pawlik Journal: J Gastrointest Surg Date: 2017-04-19 Impact factor: 3.452
Authors: Brandon C Chapman; Alessandro Paniccia; Patrick W Hosokawa; William G Henderson; Douglas M Overbey; Wells Messersmith; Martin D McCarter; Ana Gleisner; Barish H Edil; Richard D Schulick; Csaba Gajdos Journal: J Am Coll Surg Date: 2016-12-05 Impact factor: 6.113
Authors: Anuhya Kommalapati; Sri Harsha Tella; Gaurav Goyal; Mitesh Borad; Steven R Alberts; Lewis Roberts; Joleen M Hubbard; Lori Durgin; Sean Cleary; Amit Mahipal Journal: HPB (Oxford) Date: 2018-09-25 Impact factor: 3.647
Authors: Daniel J Boffa; Joshua E Rosen; Katherine Mallin; Ashley Loomis; Greer Gay; Bryan Palis; Kathleen Thoburn; Donna Gress; Daniel P McKellar; Lawrence N Shulman; Matthew A Facktor; David P Winchester Journal: JAMA Oncol Date: 2017-12-01 Impact factor: 31.777
Authors: Bolanle Asiyanbola; David Chang; Ana Luiza Gleisner; Hari Nathan; Michael A Choti; Richard D Schulick; Timothy M Pawlik Journal: J Gastrointest Surg Date: 2008-02-12 Impact factor: 3.452
Authors: Eliza W Beal; Dmitry Tumin; Dimitrios Moris; Xu-Feng Zhang; Jeffery Chakedis; Mary Dilhoff; Carl M Schmidt; Timothy M Pawlik Journal: Hepatobiliary Surg Nutr Date: 2018-08 Impact factor: 7.293
Authors: Safak Gül-Klein; Paulina Schmitz; Wenzel Schöning; Robert Öllinger; Georg Lurje; Sven Jonas; Deniz Uluk; Uwe Pelzer; Frank Tacke; Moritz Schmelzle; Johann Pratschke; Ramin Raul Ossami Saidy; Dennis Eurich Journal: Cancers (Basel) Date: 2022-06-11 Impact factor: 6.575
Authors: T Peter Kingham; Victoria G Aveson; Alice C Wei; Jason A Castellanos; Peter J Allen; Daniel P Nussbaum; Yinin Hu; Michael I D'Angelica Journal: Curr Probl Surg Date: 2020-06-30 Impact factor: 1.909
Authors: Stephen P Hack; Wendy Verret; Sohail Mulla; Bo Liu; Yulei Wang; Teresa Macarulla; Zhenggang Ren; Anthony B El-Khoueiry; Andrew X Zhu Journal: Ther Adv Med Oncol Date: 2021-07-31 Impact factor: 8.168